FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for FSHD: experimental drug losmapimod put to the test
Disease control TerminatedThis study tested a drug called losmapimod in 76 adults with facioscapulohumeral muscular dystrophy (FSHD), a rare disease that causes muscle weakness. The goal was to see if the drug is safe and can help control the disease. Participants received either losmapimod or a placebo f…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
FSHD drug trial halted: what we learned from losmapimod
Disease control TerminatedThis study tested a drug called losmapimod in 260 adults with a rare muscle disease called FSHD, which causes progressive weakness. Participants took either the drug or a placebo for 48 weeks to see if it could slow muscle decline. The trial was terminated early, so final results…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:55 UTC